Thales Papagiannakopoulos

Thales Papagiannakopoulos

Auto-generated profile, based on publicly available information

Thales Papagiannakopoulos

Department of Pathology, New York University Grossman School of Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
RRRodrigo Romero
Rodrigo Romero
VSVolkan Sayin
Volkan Sayin
SDShawn M Davidson
Shawn M Davidson
MBMatthew R Bauer
Matthew R Bauer
SSSimranjit X Singh
Simranjit X Singh
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Frequent loss-of-function mutations in KEAP1, a master regulator of the NRF2 antioxidant pathway, accelerate mutant KRAS driven lung carcinogenesis, but also impose a dependency of these tumors on glutaminolysis. Using a precision medicine–based approach, this work uncovers a metabolic vulnerability of KRAS–KEAP1-mutant lung cancers that can be therapeutically exploited using currently available glutaminase inhibitors and provides a scientific rationale for patient selection in clinical trials. Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein1. One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselves may lead to therapeutic vulnerabilities in tumors. Approximately 20% of KRAS-mutant LUAD tumors carry loss-of-function mutations in the KEAP1 gene encoding Kelch-like ECH-associated protein 1 (refs. 2, 3, 4), a negative regulator of nuclear factor erythroid 2-like 2 (NFE2L2; hereafter NRF2), which is the master transcriptional regulator of the endogenous antioxidant response5,6,7,8,9,10. The high frequency of mutations in KEAP1 suggests an important role for the oxidative stress response in lung tumorigenesis. Using a CRISPR–Cas9-based approach in a mouse model of KRAS-driven LUAD, we examined the effects of Keap1 loss in lung cancer progression. We show that loss of Keap1 hyperactivates NRF2 and promotes KRAS-driven LUAD in mice. Through a combination of CRISPR–Cas9-based genetic screening and metabolomic analyses, we show that Keap1- or Nrf2-mutant cancers are dependent on increased glutaminolysis, and this property can be therapeutically exploited through the pharmacological inhibition of glutaminase. Finally, we provide a rationale for stratification of human patients with lung cancer harboring KRAS/KEAP1- or KRAS/NRF2-mutant lung tumors as likely to respond to glutaminase inhibition.

1 July 2019 in Cell
Verified
Journal Article
Closed access
LLLuca Lignitto
Luca Lignitto
SLSarah E. LeBoeuf
Sarah E. LeBoeuf
HHHarrison Homer
Harrison Homer
SJShaowen Jiang
Shaowen Jiang
MAManor Askenazi
Manor Askenazi
MPMichele Pagano
Michele Pagano

2 October 2017 in eLife
Verified
Journal Article
Open access
VSVolkan I Sayin
Volkan I Sayin
SLSarah E LeBoeuf
Sarah E LeBoeuf
SSSimranjit X Singh
Simranjit X Singh
SDShawn M Davidson
Shawn M Davidson
DBDouglas Biancur
Douglas Biancur
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
During tumorigenesis, the high metabolic demand of cancer cells results in increased production of reactive oxygen species. To maintain oxidative homeostasis, tumor cells increase their antioxidant production through hyperactivation of the NRF2 pathway, which promotes tumor cell growth. Despite the extensive characterization of NRF2-driven metabolic rewiring, little is known about the metabolic liabilities generated by this reprogramming. Here, we show that activation of NRF2, in either mouse or human cancer cells, leads to increased dependency on exogenous glutamine through increased consumption of glutamate for glutathione synthesis and glutamate secretion by xc- antiporter system. Together, this limits glutamate availability for the tricarboxylic acid cycle and other biosynthetic reactions creating a metabolic bottleneck. Cancers with genetic or pharmacological activation of the NRF2 antioxidant pathway have a metabolic imbalance between supporting increased antioxidant capacity over central carbon metabolism, which can be therapeutically exploited.

10 July 2024 in Nature
Verified
Journal Article
Closed access
PDF file
GFGustavo S. França
Gustavo S. França
MBMaayan Baron
Maayan Baron
BKBenjamin R. King
Benjamin R. King
JBJozef P. Bossowski
Jozef P. Bossowski
ABAlicia Bjornberg
Alicia Bjornberg
IYItai Yanai
Itai Yanai

22 March 2024 in Nature Cancer
Verified
Journal Article
Closed access
KWKatherine Wu
Katherine Wu
Ahmed Ezat El ZowalatyAhmed Ezat El Zowalaty
Ahmed Ezat El Zowalaty
VSVolkan Sayin
Volkan Sayin
TPThales Papagiannakopoulos
Thales Papagiannakopoulos

25 October 2023 in Cell Reports
Verified
Journal Article
Open access
AZAnastasia-Maria Zavitsanou
Anastasia-Maria Zavitsanou
RPRay Pillai
Ray Pillai
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
EBEric Bartnicki
Eric Bartnicki
SKSergei Koralov
Sergei Koralov
Lung cancer treatment has benefited greatly through advancements in immunotherapies. However, immunotherapy often fails in patients with specific mutations like KEAP1, which are frequently found in lung adenocarcinoma. We established an antigenic lung cancer model and used it to explore how Keap1 mutations remodel the tumor immune microenvironment. Using single-cell technology and depletion studies, we demonstrate that Keap1-mutant tumors diminish dendritic cell and T cell responses driving immunotherapy resistance. This observation was corroborated in patient samples. CRISPR-Cas9-mediated gene targeting revealed that hyperactivation of the NRF2 antioxidant pathway is responsible for diminished immune responses in Keap1-mutant tumors. Importantly, we demonstrate that combining glutaminase inhibition with immune checkpoint blockade can reverse immunosuppression, making Keap1-mutant tumors susceptible to immunotherapy. Our study provides new insight into the role of KEAP1 mutations in immune evasion, paving the way for novel immune-based therapeutic strategies for KEAP1-mutant cancers.